We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Primary Care

Journal Scan / Research · September 21, 2020

No Improvement in COVID-19 With Low-Dose Hydrocortisone

JAMA: The Journal of the American Medical Association


Additional Info

JAMA: The Journal of the American Medical Association
Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial
JAMA 2020 Sep 02;[EPub Ahead of Print], PF Dequin, N Heming, F Meziani, G Plantefève, G Voiriot, J Badié, B François, C Aubron, JD Ricard, S Ehrmann, Y Jouan, A Guillon, M Leclerc, C Coffre, H Bourgoin, C Lengellé, C Caille-Fénérol, E Tavernier, S Zohar, B Giraudeau, D Annane, A Le Gouge

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading